{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:52:02Z","timestamp":1783644722449,"version":"3.55.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.autrev.2024.103543","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T15:36:46Z","timestamp":1712677006000},"page":"103543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antiphospholipid syndrome in the era of COVID-19 \u2013 Two sides of a coin"],"prefix":"10.1016","volume":"23","author":[{"given":"Naim","family":"Mahroum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Habra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Aosama","family":"Alrifaai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2024.103543_bb0005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/vms3.394","article-title":"Evolutionary study of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emerging coronavirus: phylogenetic analysis and literature review","volume":"7","author":"Tabibzadeh","year":"2021","journal-title":"Vet Med Sci"},{"issue":"10223","key":"10.1016\/j.autrev.2024.103543_bb0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103543_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2020.111255","article-title":"Risk factors for predicting mortality in elderly patients with COVID-19: a review of clinical data in China","volume":"188","author":"Leung","year":"2020","journal-title":"Mech Ageing Dev"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.18632\/aging.202456","article-title":"Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study","volume":"13","author":"Li","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"24","key":"10.1016\/j.autrev.2024.103543_bb0025","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154886","article-title":"The intersection of COVID-19 and autoimmunity","volume":"131","author":"Knight","year":"2021","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0030","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"key":"10.1016\/j.autrev.2024.103543_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2020.12.011","article-title":"COVID-19 vaccines: the status and perspectives in delivery points of view","volume":"170","author":"Chung","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"27","key":"10.1016\/j.autrev.2024.103543_bb0040","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2024.103543_bb0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"10275","key":"10.1016\/j.autrev.2024.103543_bb0050","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.autrev.2024.103543_bb0055","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"10277","key":"10.1016\/j.autrev.2024.103543_bb0060","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2024.103543_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"Kim","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0070","doi-asserted-by":"crossref","first-page":"2034456","DOI":"10.1080\/21645515.2022.2034456","article-title":"Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India","volume":"18","author":"Behera","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.autrev.2024.103543_bb0075","author":"Health NIo"},{"key":"10.1016\/j.autrev.2024.103543_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.834098","article-title":"SARS-CoV-2\u2019s variants of concern: a brief characterization","volume":"13","author":"Scovino","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103543_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.608460","article-title":"RNA vaccines: a suitable platform for tackling emerging pandemics?","volume":"11","author":"Sandbrink","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103543_bb0090","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0095","article-title":"Covid-19 vaccines and variants of concern: a review","volume":"32","author":"Hadj","year":"2022","journal-title":"Rev Med Virol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103543_bb0100","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"10.1016\/j.autrev.2024.103543_bb0105","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.autrev.2024.103543_bb0110","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the advisory committee on immunization practices - United States, July 2021","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103543_bb0120","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00296-021-05017-9","article-title":"Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study","volume":"41","author":"Esquivel-Valerio","year":"2021","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.2021012152","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know","volume":"138","author":"Arepally","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.autrev.2024.103543_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102951","article-title":"IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19","volume":"20","author":"Badier","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2024.103543_bb0135","article-title":"Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine","volume":"13","author":"Waheed","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.autrev.2024.103543_bb0140","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.kint.2021.09.009","article-title":"New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination","volume":"100","author":"Zavala-Miranda","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.autrev.2024.103543_bb0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.immuni.2020.08.003","article-title":"Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions","volume":"53","author":"Bunders","year":"2020","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.autrev.2024.103543_bb0150","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1177\/09612033231213914","article-title":"COVID-19 and SLE: infection and autoimmunity at its best","volume":"32","author":"Mahroum","year":"2023","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome","volume":"34","author":"Sammaritano","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.6530","article-title":"Prevalence of antiphospholipid antibodies and association with incident cardiovascular events","volume":"6","author":"Zuo","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.autrev.2024.103543_bb0165","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103543_bb0170","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103543_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101015","article-title":"Hematological manifestations of antiphospholipid syndrome: going beyond thrombosis","volume":"58","author":"El Hasbani","year":"2023","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.autrev.2024.103543_bb0180","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0185","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12998","article-title":"Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management","volume":"93","author":"Anka","year":"2021","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0190","first-page":"20","article-title":"COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management","volume":"29","author":"Ochani","year":"2021","journal-title":"Infez Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-2008-1066020","article-title":"Metabolic modulation of inflammation-induced activation of coagulation","volume":"34","author":"Levi","year":"2008","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0200","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.autrev.2024.103543_bb0205","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jth.15032","article-title":"Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection","volume":"18","author":"Lachant","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.autrev.2024.103543_bb0210","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.autrev.2024.103543_bb0215","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s11239-020-02242-0","article-title":"Anticoagulant treatment in COVID-19: a narrative review","volume":"51","author":"Carfora","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"10.1016\/j.autrev.2024.103543_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103206","article-title":"COVID-19 and the antiphospholipid syndrome","volume":"21","author":"Serrano","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0225","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2024.103543_bb0230","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(20)30217-9","article-title":"Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study","volume":"7","author":"Liao","year":"2020","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.autrev.2024.103543_bb0235","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103543_bb0240","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ard.56.3.194","article-title":"Thrombocytopenia in the antiphospholipid syndrome","volume":"56","author":"Cuadrado","year":"1997","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0245","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-020-01003-z","article-title":"Thrombocytopenia and thrombosis in hospitalized patients with COVID-19","volume":"13","author":"Mei","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2024.103543_bb0250","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620943293","article-title":"COVID-19-associated coagulopathy: an exacerbated Immunothrombosis response","volume":"26","author":"Jayarangaiah","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"10.1016\/j.autrev.2024.103543_bb0255","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jth.14850","article-title":"Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis","volume":"18","author":"Panigada","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.autrev.2024.103543_bb0260","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/jth.14854","article-title":"The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome","volume":"18","author":"Ranucci","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2024.103543_bb0265","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cytogfr.2021.05.001","article-title":"Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: the straw that breaks the camel\u2019s back?","volume":"60","author":"Talotta","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0270","article-title":"Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots","volume":"5","author":"Tung","year":"2021","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0275","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0961203317731532","article-title":"Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis","volume":"27","author":"Abdel-Wahab","year":"2018","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0280","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/BOR.0b013e32835448b8","article-title":"Infections and vaccines in the etiology of antiphospholipid syndrome","volume":"24","author":"Cruz-Tapias","year":"2012","journal-title":"Curr Opin Rheumatol"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2024.103543_bb0285","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12016-008-8103-0","article-title":"Infections and the antiphospholipid syndrome","volume":"36","author":"Garcia-Carrasco","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"issue":"13","key":"10.1016\/j.autrev.2024.103543_bb0290","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/0961203309345738","article-title":"Common infectious agents prevalence in antiphospholipid syndrome","volume":"18","author":"Zinger","year":"2009","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.autrev.2024.103543_bb0295","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-018-0773-x","article-title":"Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant)","volume":"20","author":"Mendoza-Pinto","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"17","key":"10.1016\/j.autrev.2024.103543_bb0300","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103543_bb0305","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11239-020-02335-w","article-title":"Lupus anticoagulant and mortality in patients hospitalized for COVID-19","volume":"52","author":"Gazzaruso","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.autrev.2024.103543_bb0315","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.thromres.2020.07.016","article-title":"Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?","volume":"195","author":"Siguret","year":"2020","journal-title":"Thromb Res"},{"issue":"570","key":"10.1016\/j.autrev.2024.103543_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3876","article-title":"Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19","volume":"12","author":"Zuo","year":"2020","journal-title":"Sci Transl Med"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2024.103543_bb0325","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1177\/096120339800700213","article-title":"Origin of antiphospholipid antibodies: induction of aPL by viral peptides","volume":"7","author":"Gharavi","year":"1998","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0330","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13054-020-03066-3","article-title":"Beta-2-glycoprotein I as a biomarker for sepsis in critically ill patients in the intensive care unit: a prospective cohort study","volume":"24","author":"Schrijver","year":"2020","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0335","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ard.2005.045443","article-title":"Infectious origin of the antiphospholipid syndrome","volume":"65","author":"Shoenfeld","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2024.103543_bb0340","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/j.seminhematol.2016.04.014","article-title":"Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine","volume":"53","author":"Bizjak","year":"2016","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0345","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0897.2008.00660.x","article-title":"Murine monoclonal antibody 26 raised against tetanus toxoid cross-reacts with beta2-glycoprotein I: its characteristics and role in molecular mimicry","volume":"61","author":"Inic-Kanada","year":"2009","journal-title":"Am J Reprod Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103543_bb0350","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/0961203311429554","article-title":"Influenza vaccination can induce new-onset anticardiolipins but not beta2-glycoprotein-I antibodies among patients with systemic lupus erythematosus","volume":"21","author":"Vista","year":"2012","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.autrev.2024.103543_bb0355","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1600-0897.2010.00922.x","article-title":"Induction of APS after TTd hyper-immunization has a different outcome in BALB\/c and C57BL\/6 mice","volume":"65","author":"Zivkovic","year":"2011","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.autrev.2024.103543_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.872683","article-title":"COVID-19 vaccination and the rate of immune and autoimmune adverse events following immunization: insights from a narrative literature review","volume":"13","author":"Mahroum","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103543_bb0365","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MBC.0000000000000963","article-title":"Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit","volume":"32","author":"Hamade","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103543_bb0370","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/jth.14867","article-title":"Lupus anticoagulant is frequent in patients with Covid-19","volume":"18","author":"Harzallah","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"18","key":"10.1016\/j.autrev.2024.103543_bb0375","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2024.103543_bb0380","author":"Agency"},{"key":"10.1016\/j.autrev.2024.103543_bb0385","author":"Agency"},{"key":"10.1016\/j.autrev.2024.103543_bb0390","article-title":"Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots","volume":"373","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.autrev.2024.103543_bb0395","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"384","author":"Skowronski","year":"2021","journal-title":"N Engl J Med"},{"issue":"Pt 3","key":"10.1016\/j.autrev.2024.103543_bb0400","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1042\/BJ20041021","article-title":"Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP)","volume":"385","author":"Nakazawa","year":"2005","journal-title":"Biochem J"},{"issue":"11","key":"10.1016\/j.autrev.2024.103543_bb0405","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.bbadis.2014.07.021","article-title":"Role of extracellular and intracellular microRNAs in sepsis","volume":"1842","author":"Essandoh","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/j.autrev.2024.103543_bb0410","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/clinchem\/48.8.1212","article-title":"Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals","volume":"48","author":"Ng","year":"2002","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.autrev.2024.103543_bb0415","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11739-021-02685-0","article-title":"Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine","volume":"16","author":"Carli","year":"2021","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.autrev.2024.103543_bb0420","series-title":"Pfizer\u2013biontech COVID-19 RNA vaccination induces phosphatidylserine autoantibodies, cryoglobulinemia, and digital necrosis in a patient with pre-existing autoimmunity","first-page":"1","volume":"1","author":"Nasr","year":"2021"},{"issue":"5","key":"10.1016\/j.autrev.2024.103543_bb0425","first-page":"1054","article-title":"Catastrophic antiphospholipid syndrome triggered by mRNA COVID-19 vaccine","volume":"40","author":"Moreno-Torres","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/mrcr\/rxac018","article-title":"Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report","volume":"7","author":"Molina-Rios","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"issue":"15","key":"10.1016\/j.autrev.2024.103543_bb0435","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.0608647104","article-title":"Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation","volume":"104","author":"Kannemeier","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.autrev.2024.103543_bb0440","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1160\/TH10-06-0345","article-title":"Expression and localisation of vascular ribonucleases in endothelial cells","volume":"105","author":"Fischer","year":"2011","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.autrev.2024.103543_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065644","article-title":"The APSANTICO study: a prospective observational study to evaluate antiphospholipid antibody profiles in patients with thromboembolic antiphospholipid syndrome (APS) after COVID-19 infection and\/or vaccination","volume":"24","author":"Ott","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2024.103543_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases\u201d","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103543_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102311","article-title":"Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications","volume":"104","author":"Xourgia","year":"2019","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.autrev.2024.103543_bb0460","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/RLU.0000000000003635","article-title":"COVID-19 vaccination manifesting as incidental lymph nodal uptake on 18F-FDG PET\/CT","volume":"46","author":"Ahmed","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.autrev.2024.103543_bb0465","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2967\/jnumed.121.262108","article-title":"(18)F-FDG-avid axillary lymph nodes after COVID-19 vaccination","volume":"62","author":"Johnson","year":"2021","journal-title":"J Nucl Med"},{"issue":"10279","key":"10.1016\/j.autrev.2024.103543_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00464-5","article-title":"(18)F-fluorodeoxyglucose PET\/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine","volume":"397","author":"Steinberg","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0475","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2017.1300522","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome","volume":"10","author":"Carmi","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103543_bb0480","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/0961203320951260","article-title":"16th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"29","author":"Cervera","year":"2020","journal-title":"Lupus"},{"issue":"3\u20134","key":"10.1016\/j.autrev.2024.103543_bb0485","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS registry\u201d","volume":"32","author":"Cervera","year":"2009","journal-title":"J Autoimmun"},{"issue":"11","key":"10.1016\/j.autrev.2024.103543_bb0490","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.autrev.2015.07.009","article-title":"The role of infectious diseases in the catastrophic antiphospholipid syndrome","volume":"14","author":"Garcia-Carrasco","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2024.103543_bb0495","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0961203309106833","article-title":"The CAPS registry: morbidity and mortality of the catastrophic antiphospholipid syndrome","volume":"18","author":"Bucciarelli","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103543_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102778","article-title":"Ferritin - from iron, through inflammation and autoimmunity, to COVID-19","volume":"126","author":"Mahroum","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103543_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0510","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2010.10.018","article-title":"Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group","volume":"124","author":"Kitchens","year":"2011","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103543_bb0515","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1586\/ehm.12.56","article-title":"Clinical causes and treatment of the thrombotic storm","volume":"5","author":"Ortel","year":"2012","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040941","article-title":"Novel coronavirus infection (COVID-19) in humans: a scoping review and Meta-analysis","volume":"9","author":"Borges do Nascimento","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2024.103543_bb0525","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.autrev.2024.103543_bb0530","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jamcollsurg.2020.05.007","article-title":"Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection","volume":"231","author":"Wright","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"7","key":"10.1016\/j.autrev.2024.103543_bb0535","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1515\/cclm-2020-0369","article-title":"Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"58","author":"Henry","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.autrev.2024.103543_bb0540","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cca.2020.03.022","article-title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis","volume":"506","author":"Lippi","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1016\/j.autrev.2024.103543_bb0545","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/ard.2003.007245","article-title":"Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies","volume":"63","author":"Espinosa","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103543_bb0550","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.imlet.2020.06.013","article-title":"Lymphopenia during the COVID-19 infection: what it shows and what can be learned","volume":"225","author":"Tavakolpour","year":"2020","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0555","first-page":"e51","article-title":"Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China","volume":"81","author":"Xu","year":"2020","journal-title":"J Inf Secur"},{"issue":"4","key":"10.1016\/j.autrev.2024.103543_bb0560","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0565","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12016-016-8568-1","article-title":"Lymphocyte disturbances in primary antiphospholipid syndrome and application to venous thromboembolism follow-up","volume":"53","author":"Simonin","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103543_bb0570","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jmv.25822","article-title":"Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis","volume":"92","author":"Cao","year":"2020","journal-title":"J Med Virol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103543_bb0575","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/ndt\/gfad077","article-title":"SARS-CoV-2 infection provoking autoimmunity","volume":"38","author":"Mahroum","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2024.103543_bb0580","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2020.04.003","article-title":"Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China","volume":"98","author":"Su","year":"2020","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.autrev.2024.103543_bb0585","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the international CAPS registry","volume":"15","author":"Rodriguez-Pinto","year":"2016","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722400034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722400034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T05:01:54Z","timestamp":1726376514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722400034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":117,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S156899722400034X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103543","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid syndrome in the era of COVID-19 \u2013 Two sides of a coin","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103543"}}